Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00334048 · ClinicalTrials.gov registry record · Phase 4
Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo
A Phase 4 study of Sexual Dysfunction, sponsored by St. Luke's-Roosevelt Hospital Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT00334048: Completed Phase 4 study of Sexual Dysfunction, sponsored by St. Luke's-Roosevelt Hospital Center.
NCT00334048 is a Phase 4 study of Sexual Dysfunction that has completed, run by St. Luke's-Roosevelt Hospital Center. The registered enrollment target is 9 participants, below the 967-participant average among 20 other Sexual Dysfunction trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00334048, a Phase 4 study of Sexual Dysfunction, has completed, sponsored by St. Luke's-Roosevelt Hospital Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
Antidepressant medicines sometimes cause sexual side effects. The purpose of this study is to determine whether the sexual dysfunction sometimes caused by selective serotonin reuptake inhibitor (SSRI) antidepressant medications can be reversed by treatment with Requip (ropinirole), a medicine which is used to treat Parkinson's Disease and restless leg syndrome.
Conditions Studied
Interventions
- DRUG Ropinirole (Requip)
Study Locations (1)
New York
- Mood Disorders Research Program - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-09 |
| Phase | Phase 4 |
What the finished NCT00334048 record still lists
NCT00334048 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 967-participant average among 20 other Sexual Dysfunction trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Sexual Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which Ropinirole (Requip) is the first listed.
NCT00334048 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00334048 about?
NCT00334048 is a clinical study titled "Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo". Antidepressant medicines sometimes cause sexual side effects. The purpose of this study is to determine whether the sexual dysfunction sometimes caused by selective serotonin reuptake inhibitor (SSRI) antidepressant medications can be reversed by treatment with Requip (ropinirole), a medicine which ...
What is the current status of trial NCT00334048?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2006-06. Estimated completion is 2007-09.
What conditions does trial NCT00334048 study?
This clinical trial studies the following conditions: Sexual Dysfunction.
What interventions are being tested in trial NCT00334048?
The interventions under investigation include: Ropinirole (Requip) (DRUG).
Who is sponsoring clinical trial NCT00334048?
This trial is sponsored by St. Luke's-Roosevelt Hospital Center, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00334048 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sexual Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00334048's enrollment target sits among peer trials
9 21st of 20 the lowest of 20 other Sexual Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sexual Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Wellbutrin XL Effects on SSRIs Induced Changes
COMPLETED · Phase 4
-
Study of Sildenafil for Treatment of SSRI-Antidepressant Sexual Dysfunction in Women
COMPLETED · Phase 4
-
A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors
RECRUITING · NA
-
Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy
RECRUITING · NA
-
Blood Specimen Collection For Laboratory Assay Research
RECRUITING
-
Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia